Proton pump inhibitor use and the risk of hepatocellular
carcinoma: A systematic review of pharmacoepidemiological data

J 2021

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

SINGH, A., Mohammad Salman HUSSAIN, R. JHA, A. S. JAYRAJ, Miloslav KLUGAR et. al.

Základní údaje

Originální název

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

Autoři

SINGH, A., Mohammad Salman HUSSAIN (356 Indie, domácí), R. JHA, A. S. JAYRAJ, Miloslav KLUGAR (203 Česká republika, domácí) a B. ANTONY (garant)

Vydání

JOURNAL OF EVIDENCE BASED MEDICINE, HOBOKEN, WILEY, 2021, 1756-5383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.224

Kód RIV

RIV/00216224:14110/21:00123257

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/jebm.12456

UT WoS

000706758800001

Klíčová slova anglicky

hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 2. 2022 11:18, Mgr. Tereza Miškechová

Anotace

V originále

Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.

Citovat

SINGH, A., Mohammad Salman HUSSAIN, R. JHA, A. S. JAYRAJ, Miloslav KLUGAR a B. ANTONY. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. JOURNAL OF EVIDENCE BASED MEDICINE. HOBOKEN: WILEY, 2021, roč. 14, č. 4, s. 278-280. ISSN 1756-5383. Dostupné z: https://dx.doi.org/10.1111/jebm.12456.

@article{1809821,
   author = {Singh, A. and Hussain, Mohammad Salman and Jha, R. and Jayraj, A. S. and Klugar, Miloslav and Antony, B.},
   article_location = {HOBOKEN},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/jebm.12456},
   keywords = {hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review},
   language = {eng},
   issn = {1756-5383},
   journal = {JOURNAL OF EVIDENCE BASED MEDICINE},
   title = {Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456},
   volume = {14},
   year = {2021}
}

TY  - JOUR
ID  - 1809821
AU  - Singh, A. - Hussain, Mohammad Salman - Jha, R. - Jayraj, A. S. - Klugar, Miloslav - Antony, B.
PY  - 2021
TI  - Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data
JF  - JOURNAL OF EVIDENCE BASED MEDICINE
VL  - 14
IS  - 4
SP  - 278-280
EP  - 278-280
PB  - WILEY
SN  - 17565383
KW  - hepatocellular carcinoma
KW  - meta-analysis
KW  - pharmacoepidemiological study
KW  - proton pump inhibitors
KW  - real-world evidence
KW  - systematic review
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456
N2  - Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.
ER  -

SINGH, A., Mohammad Salman HUSSAIN, R. JHA, A. S. JAYRAJ, Miloslav KLUGAR a B. ANTONY. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. \textit{JOURNAL OF EVIDENCE BASED MEDICINE}. HOBOKEN: WILEY, 2021, roč.~14, č.~4, s.~278-280. ISSN~1756-5383. Dostupné z: https://dx.doi.org/10.1111/jebm.12456.

Podrobný výpis o publikaci